Murine prostate cancer inhibits both In vivo and In vitro generation of dendritic cells from bone marrow precursors

被引:12
作者
Tourkova, IL
Yamabe, K
Foster, B
Chatta, G
Perez, L
Shurin, GV
Shurin, MR
机构
[1] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA USA
[2] Univ Pittsburgh, Med Ctr, Dept Med, Pittsburgh, PA USA
[3] Univ Pittsburgh, Med Ctr, Dept Immunol, Pittsburgh, PA USA
[4] Osaka Univ, Sch Med, Dept Surg 1, Suita, Osaka, Japan
[5] Roswell Pk Canc Inst, Buffalo, NY USA
关键词
prostate cancer; dendritic cell generation;
D O I
10.1002/pros.10369
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. There is increasing evidence to suggest that dendritic cells (DC) are functionally impaired in tumor bearing hosts. However there is little or no data on the effects of murine prostate cancer (CaP) on DC generation from bone marrow precursors. METHODS. Flow cytometry, mixed leukocyte reactions (MLR), and immunohistochemical analyses were used to characterize DC in CaP. RESULTS. DC generated in the presence of CaP cell lines RM1 and the cell line C2 from the transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse in a Transwell system expressed significantly lower levels of DC differentiation markers. This effect was confirmed when TK-neo-transfected RM1 cells were directly added to DC cultures and eliminated 5 days later using gancyclovir (GCV). Furthermore, co-incubation of DC with CaP cells resulted in a decrease in the stimulatory capacity of DC to induce T cell proliferation in the MLR assay. These results were further confirmed in vivo in two different murine models of CaP: i) DC generated from mice intrafemorally injected with TK-neo-transfected RMI cells; and ii) in DC generated from TRAMP mice. CONCLUSIONS. The generation and function of DC are significantly suppressed in the CaP microenvironment in both in vivo and in vitro murine models. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:203 / 213
页数:11
相关论文
共 40 条
[31]   Inhibition of CD40 expression and CD40-mediated dendritic cell function by tumor-derived IL-10 [J].
Shurin, MR ;
Yurkovetsky, ZR ;
Tourkova, IL ;
Balkir, L ;
Shurin, GV .
INTERNATIONAL JOURNAL OF CANCER, 2002, 101 (01) :61-68
[32]  
Sietsma H, 1998, CANCER RES, V58, P4840
[33]   Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation [J].
Sombroek, CC ;
Stam, AGM ;
Masterson, AJ ;
Lougheed, SM ;
Schakel, MJAG ;
Meijer, CJLM ;
Pinedo, HM ;
van den Eertwegh, AJM ;
Scheper, RJ ;
de Gruijl, TD .
JOURNAL OF IMMUNOLOGY, 2002, 168 (09) :4333-4343
[34]   Dendritic cells: Immunological sentinels with a central role in health and disease [J].
Stockwin, LH ;
McGonagle, D ;
Martin, IG ;
Blair, GE .
IMMUNOLOGY AND CELL BIOLOGY, 2000, 78 (02) :91-102
[35]   NK cells mediate Flt3 ligand-induced protection of dendritic cell precursors in vivo from the inhibition by prostate carcinoma in the murine bone marrow metastasis model [J].
Tourkova, IL ;
Yamabe, F ;
Chatta, J ;
Shurin, GV ;
Shurin, MR .
JOURNAL OF IMMUNOTHERAPY, 2003, 26 (06) :468-472
[36]   Mechanisms of dendritic cell-induced T cell proliferation in the primary MLR assay [J].
Tourkova, IL ;
Yurkovetsky, ZR ;
Shurin, MR ;
Shurin, GV .
IMMUNOLOGY LETTERS, 2001, 78 (02) :75-82
[37]  
Triest JA, 1998, CLIN CANCER RES, V4, P2009
[38]   Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer [J].
Troy, A ;
Davidson, P ;
Atkinson, C ;
Hart, D .
JOURNAL OF UROLOGY, 1998, 160 (01) :214-219
[39]  
Wu TT, 1998, INT J CANCER, V77, P887, DOI 10.1002/(SICI)1097-0215(19980911)77:6<887::AID-IJC15>3.0.CO
[40]  
2-Z